Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects



Status:Recruiting
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:2/4/2013
Start Date:September 2010
Contact:Eisai Medical Services
Phone:1-888-422-4743

Use our guide to learn which trials are right for you!

A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects


The purpose of this study is to provide data on the activity of a standard daunorubicin,
cytarabine, and etoposide (ADE) induction plus epigenetic priming with decitabine as
assessed by standard measures of complete remission (CR), leukemia free survival (LFS) and
overall survival (OS), as well as, on minimal residual disease (MRD). It will also provide
necessary data on the safety and Pharmacokinetics (PK) of decitabine in pediatric patients
that is currently unavailable.


Inclusion Criteria

1. Males and females, age 1 to 16 years, inclusive

2. Females of childbearing potential must have a negative serum beta human chorionic
gonadotropin ( B-hCG) at Visit 1 (Screening) and a negative urine pregnancy test
prior to starting study drugs (Visit 2). Female subjects of childbearing potential
must agree to be abstinent or to use a highly effective method of contraception (eg,
condom + spermicide, condom + diaphragm with spermicide, intrauterine devise (IUD),
or have a vasectomised partner) for at least one menstrual cycle prior to starting
study drug(s) and throughout the Randomization Phase or 30 days after the last dose
of study drug. Those females using hormonal contraceptives must also be using an
additional approved method of contraception (as described previously)

3. Sexually mature male patients who are not abstinent or have not undergone a
successful vasectomy, who are partners of women of childbearing potential must use,
or their partners must use a highly effective method of contraception (eg, condom +
spermicide, condom + diaphragm with spermicide, IUD) starting for at least one
menstrual cycle prior to starting study drug(s) and throughout the Randomization
Phase and for 30 days (longer if appropriate) after the last dose of study drug.
Those with partners using hormonal contraceptives must also be using an additional
approved method of contraception (as described previously)

4. Diagnosis of acute myelogenous leukemia ( AML) (bone marrow or peripheral blood
blasts greater than or equal to 20%)

5. Adequate cardiac function as defined by an echocardiogram or multiple gated
acquisition (MUGA) scan demonstrating an ejection fraction greater than 50%

6. Are willing and able to comply with all aspects of the protocol

7. Provide written informed consent from subject's guardian or legally authorized
representative and child assent (if applicable).

Exclusion Criteria

1. Females who are pregnant (positive B-hCG test) or lactating

2. History of chronic myelogenous leukemia (CML) [t(9;22)]

3. Acute promyelocytic leukemia (M3 subtype in French-American-British [FAB]
classification)

4. Known central nervous system (CNS) leukemia

5. AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom
syndrome, Kostmann syndrome, or Diamond-Blackfan anemia

6. White blood cell (WBC) count greater than 100,000/mm3

7. Serum creatinine greater than 2.5 mg/dL

8. Alanine aminotransferase (ALT) greater than 5 x upper limit of normal (ULN) and/or
total bilirubin greater than 3 x ULN

9. Prior chemotherapy (other than hydroxyurea) or radiation therapy for AML

10. Known to be human immunodeficiency virus (HIV) positive

11. Any history of or concomitant medical condition that, in the opinion of the
Investigator, would compromise the subject's ability to safely complete the study

12. The Investigator believes the subject to be medically unfit to receive the study drug
or unsuitable for any other reason

13. Subject with hypersensitivity to decitabine, daunorubicin, cytarabine, or etoposide

14. Has participated in a drug trial in the last 4 weeks.
We found this trial at
15
sites
?
mi
from
Ashville, NC
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials